



Webinar: A New Method to Assess Benefit/Risk, with Examples in Oncology
February 22, 2018 @ 11am – 12pm EST (5pm – 6pm CET)

ERRATUM

We thank you for attending our webinar last Thursday.

Please note there is a mistake in the recorded webinar on slides 45 and 46. The column labels for adverse events are reversed, and the toxicity was higher for FOLFIRINOX, the arm with higher efficacy.

As shown in slide 47, FOLFIRINOX has a net benefit that is significantly favorable regardless of the choice of threshold until 6 months, because the higher toxicity is not sufficient to offset the benefit.

Kind regards,

Marc Buyse
Chief Scientific Officer, IDDI

Everardo Saad
Medical Director, IDDI